Rebuilding Structural Integrity: Less Invasive Options for More Patients
Transcatheter Aortic Valve Replacement (TAVR)
Since participating in the initial 2007 study of transcatheter aortic valve replacement (TAVR), MHVI has been a site for every major clinical trial. After testing TAVR’s efficacy for patients at intermediate risk, MedStar Washington Hospital Center designed and launched the nation’s first multi-institutional, FDA-approved clinical trial in 2016 to evaluate the device’s benefits among low-risk patients. A separate, international study of low-risk patients is also underway at MedStar Union Memorial Hospital.
TAVR for Low-Risk Patients
In 2016, MHVI launched the first multi-institutional, clinical trial in the nation to evaluate the benefitsof using TAVR in low-risk patients. The study, based at MedStar Washington Hospital Center, will enroll up to 200 patients in several centers across the United States. A separate, international study of low-risk patients is underway at MedStar Union Memorial Hospital.
“We can often use a catheterbased strategy to treat structural disease and get the same result as a standard openchest operation, thanks to our experience combining interventional, surgical and imaging techniques.” - Lowell Satler, MD
Highlights of the Structural Heart Program:
- A combined average of 340 TAVR procedures annually at MHVI's two anchor hospitals
- A multidisciplinary, structural heart team comprising cardiovascular surgeons, interventional cardiologists and cardiovascular imaging specialists. The Structural Heart Team convenes daily to discuss and analyze all patients that are screened for any structural heart procedure at MedStar Washington Hospital Center.
- A Structural Heart Clinic for comprehensive patient evaluation and management
- Access to innovative therapies though the MedStar Cardiovascular Research Network (MCRN)
Read More in the Capabilities Booklet:
To make the book full screen, click on the last icon to the right.